News

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

Neuen describes varying treatment effects with 4 different classes of IgAN therapeutics and future opportunities for personalized treatment.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.

This interview highlighted findings on actinic keratosis following treatment with tirbanibulin.

CBT-I improved sleep outcomes and achieved 54% remission in patients with chronic pain, cancer, cardiovascular disease, and other chronic conditions.

Both ACOG and AAP have released statements disagreeing with the FDA label change for acetaminophen to reflect autism risk in children if used during pregnancy.

Investigators have highlighted diabetes and obesity as leading drivers of steadily increasing global cardiovascular mortality rates.

Staller describes unmet needs in gastroparesis and key recommendations for its diagnosis and management from the new AGA guidelines.

A compiled list of the 8 most exciting presentations scheduled for the Heart Failure Society of American Annual Scientific Meeting 2025.

Despite prior trials indicating the possibility, the AUSPICE study failed to display any difference in risk between patients receiving the vaccine versus placebo.

In a study, the prevalence of transthyretin cardiac amyloidosis reached 17% in Black men over 75 years old.

Findings from an analysis of GBD 2021 data highlight increases in the absolute number of ASCVD cases and deaths among the working-age population.

AKINESIS study finds kidney tubule biomarker IGFBP‑7 predicts 1-year death and heart failure readmission in acute heart failure patients.

New research supports fimasartan, atorvastatin, and ezetimibe combination to blood pressure and cholesterol levels.

This Sickle Cell Awareness Month, HCPLive draws attention to recent advancements made in SCD treatment and how much still needs to be done to address it.

Findings suggest post-stroke dysphagia is associated with adverse psychosocial outcomes at 3 months, emphasizing the need for comprehensive rehabilitation strategies.

Parent company CeleCor Therapeutics announced positive safety and efficacy endpoint data for their investigative GPIIb/IIIa inhibitor versus placebo.

Although PREVENT was more consistent among the overall population, PCE saw more accurate readings in those taking statins within the trial period.

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

This September 22 Savvy Conversations episode features a conversation on vitiligo and its impact on patients of diverse skin types.

Phase 3 STRIVE-ON Safety Trial results were presented at the 2025 Neurocritical Care Society annual meeting and suggest GTx-104’s viability over oral nimodipine.

Cytisinicline shows promise as a safe and effective smoking cessation treatment, significantly improving quit rates in COPD.

Neuen reviews recent advances in IgAN treatment and findings from a systematic review and meta-analysis guiding their use in clinical practice.

A significant amount of TED cases go undiagnosed due to a lack of routine screening – Khachikian discusses what is needed to address this problem.

Research suggests emergency department–discharged children rarely return within 7 days, questioning routine corticosteroid use for mild-to-moderate reactions.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New findings from the POSITIVE trial highlight tildrakizumab's effectiveness in enhancing quality of life for psoriatic disease patients.

Ruxolitinib cream shows promising results in prurigo nodularis, with significant symptom improvements and strong safety profiles.